Advanced Search
WANG Yixin, HU Zongtao, ZHANG Yongkang, ZENG Ping, WANG Hongzhi. Safety and Clinical Efficacy of PD-1 on Advanced Primary Hepatocellular Carcinoma[J]. Cancer Research on Prevention and Treatment, 2020, 47(4): 298-302. DOI: 10.3971/j.issn.1000-8578.2020.19.1112
Citation: WANG Yixin, HU Zongtao, ZHANG Yongkang, ZENG Ping, WANG Hongzhi. Safety and Clinical Efficacy of PD-1 on Advanced Primary Hepatocellular Carcinoma[J]. Cancer Research on Prevention and Treatment, 2020, 47(4): 298-302. DOI: 10.3971/j.issn.1000-8578.2020.19.1112

Safety and Clinical Efficacy of PD-1 on Advanced Primary Hepatocellular Carcinoma

More Information
  • Corresponding author:

    WANG Hongzhi, E-mail: wanghz@hfcas.ac.cn

  • Received Date: September 01, 2019
  • Revised Date: December 19, 2019
  • Available Online: January 12, 2024
  • Objective 

    To observe the short-term clinical effect and total survival of advanced hepatocellular carcinoma patients treated with PD-1.

    Methods 

    We retrospectively analyzed the clinical data of 48 patients with advanced hepatocellular carcinoma treated with PD-1 monoclonal antibody (observation group) and 55 patients with advanced hepatocellular carcinoma treated with apatinib mesylate(control group). Short-term clinical effect, overall survival and adverse reactions were analyzed.

    Results 

    The AFP, ALT, AST, ECOG, Child-Paugh score, objective remission rate and disease control rate in the observation group were better than those in the control group (P < 0.05), and the overall survival in the observation group (95%CI: 7.24-8.64 months) was significantly longer than that in the control group (95%CI: 5.13-6.39 months) (P < 0.05). There were significant differences in rashes, nausea, vomiting and adverse reactions of hypertension between two groups (P < 0.05).

    Conclusion 

    Compared with apatinib mesylate, PD-1 could improve the short-term clinical efficacy and prolong the overall survival of patients with advanced hepatocellular carcinoma.

  • [1]
    Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132.
    [2]
    Huang ZY, Liang BY, Xiong M, et al. Long-term Outcomes of Repeat Hepatic Resection in Patients with Recurrent Hepatocellular Carcinoma and Analysis of Recurrent Types and Their Prognosis: A Single-Center Experience in China[J]. Ann Surg Oncol, 2012, 19(8): 2515-2525.
    [3]
    Salmaninejad A, Valilou SF, Shabgah AG, et al. PD-1/PD-L1 pathway: Basic biology and role in cancer immunotherapy[J]. J Cell Physiol, 2019, 234(10): 16824-16837.
    [4]
    Liu B, Arakawa Y, Yokogawa R, et al. PD-1/PD-L1 expression in a series of intracranial germinoma and its association with Foxp3+ and CD8+ infiltrating lymphocytes[J]. PLoS One, 2018, 13(4): e0194594.
    [5]
    Kline J, Gajewski TF. Clinical development of mAbs to block the PD1 pathway as an immunotherapy for cancer[J]. Curr Opin Investig Drugs, 2010, 11(12): 1354-1359.
    [6]
    Sharma P, Allison JP. The future of immune checkpoint therapy[J]. Science, 2015, 348(6230): 56-61.
    [7]
    Liu B, Song Y, Liu D. Recent development in clinical applicationsof PD-1 and PD-L1 antibodies for cancer immunotherapy[J]. J Hematol Oncol, 2017, 10(1): 174.
    [8]
    Chang H, Jung W, Kim A, et al. Expression and prognostic significance of programmed death protein 1 and programmed death ligand-1, and cytotoxic T lymphocyte-associated molecule-4 in hepatocellularcarcinoma[J]. APMIS, 2017, 125(8): 690-698.
    [9]
    Butte MJ, Keir ME, Phamduy TB, et al. Programmed Death-1 Ligand 1 Interacts Specifically with the B7-1 Costimulatory Molecule to Inhibit T Cell Responses[J]. Immunity, 2007, 27(1): 111-122.
    [10]
    Scheiner B, Kirstein MM, Hucke F, et al. Programmed cell death protein-1 (PD-1)-targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real-world cohort[J]. Aliment Pharmacol Ther, 2019, 49(10): 1323-1333.
    [11]
    Peng S, Zhang Y, Peng H, et al. Intracellular autocrine VEGF signaling promotes EBDC cell proliferation, which can be inhibited by Apatinib[J]. Cancer Lett, 2016, 373(2): 193-202.
    [12]
    Scott AJ, Messersmith WA, Jimeno A. Apatinib: a promising oral antiangiogenic agent in the treatment of multiple solid tumors[J]. Drugs Today (Barc), 2015, 51(4): 223-229.
    [13]
    秦叔逵, 白玉贤, 欧阳学农, 等.阿帕替尼一线治疗晚期肝细胞癌的前瞻性、随机、开放、全国多中心Ⅱ期临床试验[J].临床肿瘤学杂志, 2017, 22(12): 1057-1065.

    Qin SK, Bai YX, Ouyang XN, et al. Apatinib for patients with advanced hepatocellular carcinoma: a randomised, open-label, multicentre, phaseⅡ clinical trial[J]. Lin Chuang Zhong Liu Xue Za Zhi, 2017, 22(12): 1057-1065.
    [14]
    Crocenzi TS, Ei-Khoueiry AB, Yau TC, et al. Nivolumab (nivo) in sorafenib(sor)-naive and -experienced pts with advanced hepatocellular carcinoma(HCC): CheckMate 040 study[J]. J Clin Oncol, 2017, 35: 4013.
    [15]
    Stucci S, Palmirotta R, Passarelli A, et al. Immune-related adverse events during anticancer immunotherapy: Pathogenesis and management (Review)[J]. Oncol Lett, 2017, 14(5): 5671-5680.
    [16]
    Naidoo J, Page DB, Li BT, et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies[J]. Ann Oncol, 2016, 27(7): 1362.
    [17]
    Nishino M, Sholl LM, Hodi FS, et al. Anti-PD-1-related pneumonitis during cancer immunotherapy[J]. N Engl J Med, 2015, 373(3): 288-290.
    [18]
    Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer[J]. N Engl J Med, 2015, 372(21): 2018-2028.
    [19]
    Gettinger SN, Horn L, Gandhi L, et al. Overall survival and long term safety of nivolumab (anti-programmed death 1 antibody, bms-936558, ono-4538) in patients with previously treatedadvanced non-small-cell lung cancer[J]. J Clin Oncol, 2015, 33(18): 2004-2012.
    [20]
    Hofmann L, Forschner A, Loquai C, et al. Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy[J]. Eur J Cancer, 2016, 60: 190-209.
  • Related Articles

    [1]HE Jiawei, CAO Longnyu, TANG Mengyuan, CUI Hongquan. Causal Relationships Between Immune Cells and Risk of Gastric Cancer: A Mendelian Randomization Study[J]. Cancer Research on Prevention and Treatment, 2025, 52(2): 172-176. DOI: 10.3971/j.issn.1000-8578.2025.24.0438
    [2]WU Tong, GAO Fei, TENG Fei, ZHANG Qiaoli. Genetic Determinants of Immune Cells and Hepatocellular Carcinoma Risk: A Bioinformatics and Bidirectional Mendelian Randomization Study[J]. Cancer Research on Prevention and Treatment, 2025, 52(1): 42-51. DOI: 10.3971/j.issn.1000-8578.2025.24.0562
    [3]YUAN Chendong, SHU Xufeng, WANG Xiaoqiang, JIE Zhigang. Relationship Between High-Density Lipoprotein Cholesterol and Colorectal Cancer—A Mendelian Randomization Study[J]. Cancer Research on Prevention and Treatment, 2024, 51(10): 847-851. DOI: 10.3971/j.issn.1000-8578.2024.24.0153
    [4]GONG Wanli, HOU Yaqi, WANG Yue, LI Yuan, QI Rongxuan, YU Qi, ZHANG Juan. Immune Cell-Mediated Effect of Lipid Profile on Colorectal Cancer: A Two-Step, Two-Sample Mendelian Randomization Study[J]. Cancer Research on Prevention and Treatment, 2024, 51(10): 831-839. DOI: 10.3971/j.issn.1000-8578.2024.24.0284
    [5]LIU Jingting, ZHOU Yawei, KONG Lingguo, WANG Qiandan, SU Tianxiong, PEI Jianying, LI Yan. Causal Association Between Immune Cells and Cervical Cancer: A Two-Sample Mendelian Randomization Study[J]. Cancer Research on Prevention and Treatment, 2024, 51(9): 772-778. DOI: 10.3971/j.issn.1000-8578.2024.24.0037
    [6]WANG Yuanhang, SONG Zhiyuan, LU Ping, ZHANG Min. Analysis of Association Between Immune Cells and Breast Cancer Based on Two-sample Mendelian Randomization Method[J]. Cancer Research on Prevention and Treatment, 2024, 51(5): 348-352. DOI: 10.3971/j.issn.1000-8578.2024.23.1125
    [7]LIU Longjiao, YAO Yufeng. Circulating Inflammatory Proteins in Relation to Risk of Breast Cancer: A Two-sample Mendelian Randomization Study[J]. Cancer Research on Prevention and Treatment, 2024, 51(5): 342-347. DOI: 10.3971/j.issn.1000-8578.2024.23.1344
    [8]WEI Wei, LIU Ming, XU Jianguo, GAO Ya, SHEN Caiyi, TIAN Jinhui. Causal Relationship Between Acromegaly and Colon Cancer: A Two-sample Mendelian Randomization Study[J]. Cancer Research on Prevention and Treatment, 2023, 50(12): 1209-1213. DOI: 10.3971/j.issn.1000-8578.2023.23.0507
    [9]WANG Mengyuan, XU Hengmin, WANG Jingxuan, PAN Kaifeng, LI Wenqing. Mendelian Randomization Analysis of Research on Risk Factors for Gastric Cancer[J]. Cancer Research on Prevention and Treatment, 2023, 50(5): 470-476. DOI: 10.3971/j.issn.1000-8578.2023.22.1411
    [10]Xin-ying ZHOU, Hu ZHANG, Hai-yan DAI. Mendelian randomization analysis of the correlation between interleukin and the risk of gynecological tumors[J]. Cancer Research on Prevention and Treatment. DOI: 10.3971/j.issn.1000-8578.20240994
  • Cited by

    Periodical cited type(13)

    1. 吴杨,隋雨桐,李斌鹏,韩路拓,姜家康. 激酶/转录因子信号通路调控肺癌机制及中医药干预的研究进展. 世界中医药. 2025(01): 142-147+154 .
    2. 曹家瑞,冯博,马纯政,陈伟霞,喻江凡,曹莎莎,张振予,欧阳文慧. 中医药调控JAK/STAT信号通路干预肺癌的机制研究进展. 中国实验方剂学杂志. 2025(09): 265-276 .
    3. 梁帅,尹怡,刘湘花,汪保英,骆文龙,龙云凯,任振杰,王祥麒. 升降理肺消瘤汤对Lewis肺癌小鼠免疫炎性反应和JAK2/STAT3信号通路的影响. 辽宁中医药大学学报. 2024(04): 27-32 .
    4. 张彩蝶,靳艳,张德德. 润肺益肾饮对肺癌荷瘤大鼠的抑瘤作用和肿瘤免疫微环境的影响. 天津医药. 2024(04): 362-366 .
    5. 孙喜,王召路,贾谨睿,王梦洋,孙润卓,王鹏,史新娥. 虫草素及其在生猪养殖中的应用. 畜牧兽医杂志. 2024(04): 1-7 .
    6. 兰春燕,杨小兰,贺雪峰,赵丹,杨海燕. 甘草苷对胃癌荷瘤小鼠免疫功能的调节作用及机制研究. 中国药房. 2024(15): 1862-1867 .
    7. 张景淇,郭静,陈娅欣,蒲玥衡,向俊杰. 中药调控肺癌相关信号通路研究进展. 中国实验方剂学杂志. 2024(19): 233-244 .
    8. 张孟恩,韩睿,徐超,庞训胜,王世琴. 地顶孢霉培养物在反刍动物生产中的应用研究进展. 中国畜牧杂志. 2024(12): 70-74 .
    9. 高铭,丁美灵,雷紫琴,胡靖文,栾飞,曾南. 荆防败毒散及其中成药制剂研究进展. 中药药理与临床. 2023(05): 112-118 .
    10. 朱亚兰,吕世文,曾晨欣,徐媛青. 苍术素对非小细胞肺癌细胞上皮间质转化的影响及机制研究. 浙江医学. 2023(10): 1013-1018 .
    11. 陈才伟,陈家亮,李华娟,方芳,文方玲. 虫草素调节MAPK/AP-1信号通路对慢性阻塞性肺疾病大鼠肺组织损伤的影响. 临床肺科杂志. 2023(11): 1656-1661 .
    12. 李翔子,王西双,范建伟,杨田野,王丽娟,孙颖,姚景春. 荆防合剂通过抑制JAK2-STAT3信号通路调节荨麻疹小鼠脾脏T淋巴细胞亚群的平衡. 中国中药杂志. 2022(20): 5473-5480 .
    13. 沈栩岚,黄凌霞. 虫草素的抗癌机理. 蚕桑通报. 2022(02): 33-34 .

    Other cited types(4)

Catalog

    Article views PDF downloads Cited by(17)

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return